文献速递肿瘤 PET/CT

前列腺癌原发分期中[68Ga]Ga-PSMA-11 PET/CT假阳性病灶的病理与影像学特征:放射-病理匹配分析

Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT in primary staging of prostate cancer: a radio-pathology matching analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-02-17

该研究回顾性分析216例根治性前列腺切除术前接受[68Ga]Ga-PSMA-11 PET/CT的前列腺癌患者,共识别36个假阳性病灶(PET/CT可疑且PRIMARY评分≥3但全切片病理良性)。假阳性病灶中以伴囊性变的单纯萎缩最常见(69.44%),显著高于真阴性病灶(22.22%;P < 0.001),且假阳性病灶SUVmax与SUVmean均显著低于真阳性病灶(均P < 0.001)。

要点

  • 伴囊性变的单纯萎缩是[68Ga]Ga-PSMA-11 PET/CT假阳性病灶的突出病理特征(69.44%)。
  • 假阳性病灶PSMA表达经免疫组化证实,可能解释其摄取增高。
  • 假阳性病灶SUVmax与SUVmean均显著低于真阳性病灶(均P < 0.001)。

核心结论

  • 伴囊性变的单纯萎缩是[68Ga]Ga-PSMA-11 PET/CT假阳性病灶的突出病理特征。
  • 该现象可能归因于伴囊性变的单纯萎缩中PSMA表达升高,经组织学分析证实。
  • 假阳性病灶SUV显著低于真阳性病灶。

研究设计与样本

  • 回顾性分析216例根治性前列腺切除术前接受[68Ga]Ga-PSMA-11 PET/CT的前列腺癌患者。
  • 假阳性病灶定义为PET/CT可疑且PRIMARY评分≥3但全切片病理良性;真阴性病灶为PSMA PET/CT无摄取区且全切片病理良性,随机勾画。
  • 采用Fisher精确检验比较假阳性与真阴性病灶的病理特征,采用Wilcoxon配对符号秩检验比较假阳性与真阳性病灶的SUVmax和SUVmean。
  • 通过免疫组化评估假阳性病灶的PSMA表达。

主要发现

  • 共识别36个假阳性病灶:伴囊性变的单纯萎缩25个(69.44%)、前列腺结节性增生7个(19.44%)、炎症3个(8.33%)、正常腺体1个(2.78%)。
  • 勾画36个真阴性病灶:正常腺体21个(58.33%)、伴囊性变的单纯萎缩8个(22.22%)、前列腺结节性增生6个(16.67%)、炎症1个(2.78%)。
  • 伴囊性变的单纯萎缩在假阳性病灶与真阴性病灶中的比例分别为69.44%与22.22%,差异有统计学意义(P < 0.001)。
  • 假阳性病灶与真阳性病灶的SUVmax和SUVmean差异均有统计学意义(均P < 0.001)。
  • 免疫组化证实假阳性病灶存在PSMA表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to investigate the radiological and pathological characteristics of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT during the primary staging of prostate cancer. METHODS: This study retrospectively analyzed 216 prostate cancer patients who had [68Ga]Ga-PSMA-11 PET/CT before radical prostatectomy. False-positive lesion was defined as suspicious lesion with PRIMARY score ≥ 3 on PET/CT but benign on whole-mount pathology. To analyze the radiological and pathological features of false-positive lesions, no-uptake areas on PSMA PET/CT with benign pathology on the whole-mount specimen were randomly delineated and defined as true-negative lesions. The pathological features of false-positive and true-negative lesions were compared using Fisher's exact test. The differences of SUVmax and SUVmean between false-positive and true-positive lesions were determined and compared using the Wilcoxon matched-pairs signed-ranks test. In addition, PSMA expression in false-positive lesions was assessed by immunohistochemistry. RESULTS: A total of 36 false-positive lesions were identified on [68Ga]Ga-PSMA-11 PET/CT: 25 (69.44%) were simple atrophy with cyst formation, 7 (19.44%) were prostatic nodular hyperplasia, 3 (8.33%) were inflammation and 1 (2.78%) was normal glands. A comparable number of 36 true-negative lesions were delineated: 21 (58.33%) were normal glands, 8 (22.22%) were simple atrophy with cyst formation, 6 (16.67%) were prostatic nodular hyperplasia, and 1 (2.78%) were inflammation. The Fisher's exact test revealed a statistically significant difference in the prevalence of simple atrophy with cyst formation between false-positive and true-negative lesions (69.44% vs. 22.22%; P < 0.001). Differences in SUVmax and SUVmean between false-positive and true-positive lesions were also statistically significant (both P < 0.001). PSMA expression in false-positive lesions was confirmed via immunohistochemistry. CONCLUSION: This study determined that simple atrophy with cyst formation is a distinctive pathological feature of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT. This observation is likely attributable to the elevated PSMA expression in simple atrophy with cyst formation, as confirmed by histological analysis. Additionally, false-positive lesions were found to have significantly lower SUV compared to true-positive lesions.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li R, Fu Y, Peng S, et al. Pathological and radiological features of false-positive lesions on [68Ga]Ga-PSMA-11 PET/CT in primary staging of prostate cancer: a radio-pathology matching analysis. Eur J Nucl Med Mol Imaging. 2025. PMID: 39960655. doi:10.1007/s00259-025-07148-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。